Your browser doesn't support javascript.
loading
RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer.
O'Malley, David M; Randall, Leslie M; Jackson, Camille Gunderson; Coleman, Robert L; Hays, John L; Moore, Kathleen N; Naumann, R Wendel; Rocconi, Rodney P; Slomovitz, Brian M; Tewari, Krishnansu S; Ancukiewicz, Marek; Feliu, Waldo Ortuzar; Monk, Bradley J.
Afiliação
  • O'Malley DM; Division of Gynecologic Oncology, The Ohio State University/James Comprehensive Cancer Center, Columbus, OH 43210, USA.
  • Randall LM; Division of Gynecologic Oncology, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
  • Jackson CG; Department of Obstetrics & Gynecology, Stephenson Oklahoma Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
  • Coleman RL; Department of Gynecologic Oncology & Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Hays JL; Division of Gynecologic Oncology, The Ohio State University/James Comprehensive Cancer Center, Columbus, OH 43210, USA.
  • Moore KN; Department of Obstetrics & Gynecology, Stephenson Oklahoma Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
  • Naumann RW; Department of Gynecologic Oncology, Levine Cancer Institute, Charlotte, NC 28204, USA.
  • Rocconi RP; Department of Obstetrics & Gynecology, University of South Alabama Mitchell Cancer Institute, Mobile, AL 36604, USA.
  • Slomovitz BM; Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA.
  • Tewari KS; Division of Gynecologic Oncology, University of California, Irvine Medical Center, Orange, CA 92868, USA.
  • Ancukiewicz M; Agenus, Inc., Lexington, MA 02421, USA.
  • Feliu WO; Agenus, Inc., Lexington, MA 02421, USA.
  • Monk BJ; Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona & Creighton University, Phoenix, AZ 85016, USA.
Future Oncol ; 17(26): 3433-3443, 2021 Sep.
Article em En | MEDLINE | ID: mdl-34409858
Lay abstract Current treatment options for women with recurrent/metastatic cervical cancer are limited. Immunotherapy is altering the therapeutic landscape in this setting yet opportunities remain to improve on current outcomes. Dual blockade of different immune checkpoints is an approach shown to be highly effective in other cancers. Balstilimab (anti-programmed death 1) and zalifrelimab (anti-CTLA-4) are two new checkpoint inhibitors showing promise in patients with advanced cervical cancer. The RaPiDS trial is designed to characterize the safety and activity of balstilimab, alone and in combination with zalifrelimab, in patients with recurrent/metastatic cervical cancer who progressed after prior platinum-based chemotherapy. Clinical trial registration: NCT03894215 (ClinicalTrials.gov).
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 6_cervical_cancer Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Ensaios Clínicos Controlados Aleatórios como Assunto / Neoplasias do Colo do Útero / Ensaios Clínicos Fase II como Assunto / Inibidores de Checkpoint Imunológico Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Future Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 6_cervical_cancer Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Ensaios Clínicos Controlados Aleatórios como Assunto / Neoplasias do Colo do Útero / Ensaios Clínicos Fase II como Assunto / Inibidores de Checkpoint Imunológico Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Future Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos